Literature DB >> 28396932

Comparison of analgaesia with lumbar epidurals and lumbar plexus nerve blocks in patients receiving multimodal analgaesics following primary total hip arthroplasty: a retrospective analysis.

N Robert Harvey1, Bethany J Wolf2, Eric D Bolin3, Sylvia H Wilson3.   

Abstract

PURPOSE: Significant post-operative pain occurs after hip arthroplasty. In a prior study, lumbar plexus nerve blocks provided comparable analgaesia to lumbar epidurals; however, multimodal analgaesics were not used consistently.
METHODS: This study assessed a randomly selected cohort of 48 patients undergoing primary hip arthroplasty who received a regional anaesthesia technique for post-operative pain. Twenty-four patients with lumbar epidurals and 24 with single-injection lumbar plexus nerve blocks were reviewed using electronic medical records. Post-operative opiate consumption was the primary endpoint. Secondary endpoints were participation in physical therapy, side effects, and time to discharge. Descriptive statistics were calculated to describe patients in the different groups. Opiate consumption was compared using linear mixed models. Multivariable models were examined for both primary and secondary endpoints.
RESULTS: In comparison with patients receiving lumbar epidural catheters, patients with lumbar plexus blocks consumed less opiates post-operatively at 24-36 and 36-48 hours (P = 0.037 and 0.002, respectively); it did not differ at zero to 12 hours or 12-24 hours post-operatively. Patients with lumbar plexus blocks had earlier times to first ambulation (28.5 ± 3.29 vs 21.9 ± 1.76 h; P = 0.043). However, differences by block type were not observed for ambulation distance, level of assistance to ambulate or time of discharge orders.
CONCLUSIONS: Following primary total hip arthroplasty, lumbar plexus nerve blocks provide effective post-operative analgaesia with decreased opiate consumption compared with lumbar epidural catheters. Lumbar plexus blocks also promote earlier post-operative ambulation and are compatible with post-operative prophylactic anticoagulants.

Entities:  

Keywords:  Analgaesia; Anesthaesia; Arthroplasty; Epidural; Hip replacement; Nerve block; Pain; Post-operative

Mesh:

Substances:

Year:  2017        PMID: 28396932      PMCID: PMC7179727          DOI: 10.1007/s00264-017-3465-7

Source DB:  PubMed          Journal:  Int Orthop        ISSN: 0341-2695            Impact factor:   3.075


  20 in total

Review 1.  Epidural analgesia for pain relief following hip or knee replacement.

Authors:  P T Choi; M Bhandari; J Scott; J Douketis
Journal:  Cochrane Database Syst Rev       Date:  2003

2.  Comparison of Lumbar Epidurals and Lumbar Plexus Nerve Blocks for Analgesia Following Primary Total Hip Arthroplasty: A Retrospective Analysis.

Authors:  Sylvia H Wilson; Bethany J Wolf; Abdalrahman A Algendy; Clark Sealy; Harry A Demos; Julie R McSwain
Journal:  J Arthroplasty       Date:  2016-08-10       Impact factor: 4.757

3.  Influence of cochlear implantation on the vestibular function.

Authors:  Eirini Katsiari; Dimitrios G Balatsouras; John Sengas; Maria Riga; George S Korres; John Xenelis
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-04-06       Impact factor: 2.503

4.  Lumbar plexus block reduces pain and blood loss associated with total hip arthroplasty.

Authors:  R D Stevens; E Van Gessel; N Flory; R Fournier; Z Gamulin
Journal:  Anesthesiology       Date:  2000-07       Impact factor: 7.892

5.  Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition).

Authors:  Terese T Horlocker; Denise J Wedel; John C Rowlingson; F Kayser Enneking; Sandra L Kopp; Honorio T Benzon; David L Brown; John A Heit; Michael F Mulroy; Richard W Rosenquist; Michael Tryba; Chun-Su Yuan
Journal:  Reg Anesth Pain Med       Date:  2010 Jan-Feb       Impact factor: 6.288

6.  Predictors of pain and use of pain medications following primary Total Hip Arthroplasty (THA): 5,707 THAs at 2-years and 3,289 THAs at 5-years.

Authors:  Jasvinder A Singh; David Lewallen
Journal:  BMC Musculoskelet Disord       Date:  2010-05-13       Impact factor: 2.362

Review 7.  Health-related quality of life in total hip and total knee arthroplasty. A qualitative and systematic review of the literature.

Authors:  Olivier Ethgen; Olivier Bruyère; Florent Richy; Charles Dardennes; Jean-Yves Reginster
Journal:  J Bone Joint Surg Am       Date:  2004-05       Impact factor: 5.284

Review 8.  Psoas compartment block for lower extremity surgery: a meta-analysis.

Authors:  S T Touray; M A de Leeuw; W W A Zuurmond; R S G M Perez
Journal:  Br J Anaesth       Date:  2008-10-22       Impact factor: 9.166

9.  Continuous lumbar plexus block for postoperative pain control after total hip arthroplasty. A randomized controlled trial.

Authors:  Joseph Marino; Joseph Russo; Maureen Kenny; Robert Herenstein; Elayne Livote; Jacques E Chelly
Journal:  J Bone Joint Surg Am       Date:  2009-01       Impact factor: 5.284

Review 10.  The efficacy of preoperative administration of gabapentin/pregabalin in improving pain after total hip arthroplasty: a meta-analysis.

Authors:  Yingdelong Mao; Lianguo Wu; Weiguo Ding
Journal:  BMC Musculoskelet Disord       Date:  2016-08-30       Impact factor: 2.362

View more
  3 in total

1.  Citations, non-citations and visibility of International Orthopaedics in 2017.

Authors:  Andreas F Mavrogenis; Andrew Quaile; Marko Pećina; Marius M Scarlat
Journal:  Int Orthop       Date:  2018-11       Impact factor: 3.075

2.  Impact of Ketorolac on Opioid Consumption after Knee Arthroscopy.

Authors:  S H Wilson; H Slone; C M Furse; T I Epperson; B J Wolf
Journal:  Austin J Anesth Analg       Date:  2018-11-08

Review 3.  Liposomal bupivacaine versus traditional bupivacaine for pain control after total hip arthroplasty: A meta-analysis.

Authors:  Ting-Ting Ma; Yu-Hui Wang; Yun-Feng Jiang; Cong-Bin Peng; Chao Yan; Zi-Gui Liu; Wei-Xing Xu
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.